




Hypothyroidism



References

1. Mestman JH. Diagnosis and management of maternal and fetal thyroid disorders. **Curr Opin Obstet Gynecol 1999;11:167-75.** *Indications for thyroid testing in pregnancy.*
2. Mandel SL, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. **N Engl J Med 1990; 323:91 -6.** *For patients with a history of thyroid disease, a free T4 measurement is indicated in addition to the TSH. Mild elevations of TSH are frequently found in hypothyroid women on replacement therapy after conception because of the increased demand for thyroid hormones in pregnancy.*
3. 3) Kilpatrick S. Umbilical blood sampling in women with thyroid disease in pregnancy: Is it necessary? **Am J Obstet Gynecol 2003;189:1-2.** *TSAb should be done on women with history of treatment with I31I or with a previously affected neonate. PUBS should be offered to pregnant women with Graves' disease if any one of the following are present: a) a history of a prior affected baby, b) a history of maternal I31I treatment and a high TSAb level (>5IU or >160%), c) the fetus displays fetal tachycardia, growth restriction, fetal goiter, hydrops or cardiomegaly.*
4. Mestman JH. Endocrine Diseases in Pregnancy. **Obstetrics: Normal and Problem Pregnancies. 4th ed Churchill Livingstone: Philadelphia: 2002.** *Symptoms include tiredness, cold intolerance, fatigue, muscle cramps, constipation and deepening of the voice. Most pregnant women tolerate an initial dose of 0.15mg/day of thyroxine. The maintenance dose required by most patients is between 0.125 and 0.25mg daily.*
5. Wiersinga WM. Thyroid hormone replacement therapy. **Horm Res 2001;56:74-81.** *If the patient is overtreated, it is reasonable to start with a decrease in the replacement dose by half. An accurate prediction of the finally required levothyroxine dose can be obtained by the equation: Levothyroxine (daily dose in µg) = -14 + (4.1 x TSH mU/l)*
6. Seely BL, Burrow GN. Thyroid Disease and Pregnancy. **Maternal Fetal Medicine 4th ed. WB Saunders Co. Philadelphia:1999, 1009.** *Women with thyroid disease prior to pregnancy commonly require increases in their dosage as the pregnancy progresses. Checking TSH each trimester is recommended to monitor dosage adjustments. After delivery, restart the initial dose prior to pregnancy.*
7. Subclinical hypothyroidism in pregnancy. ACOG Committee Opinion. No. 381. American College of Obstetricians and Gynecologists. **Obstet Gynecol 2007; 110:959-60. Reaffirmed 2010.** *Thyroid testing in pregnancy should be performed on symptomatic women and those with a personal history of thyroid disease or medical conditions associated with thyroid disease. Routine screening and treatment for subclinical hypothyroidism is currently not recommended and there is no prospective, controlled evidence that treatment improves maternal or infant outcomes.*

8. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. **Thyroid** 2011;21:1061-1124. *Definitions of thyroid disorders in pregnancy include: overt hypothyroidism – OH- (TSH > 2.5 mIU/L and decreased free T4 or TSH > 10 mIU/L; subclinical hypothyroidism- SCH - (TSH between 2.5 and 10 mIU/L with normal free T4; isolated hypothyroxinemia- IH- (normal TSH with free T4 < 10th % tile of reference range). Gestational age specific ranges for TSH should be used for diagnosis and management of adequacy of replacement therapy. Optimal assessment of thyroid status in pregnancy is free T4 by liquid chromatography/tandem mass spec with TSH being a more accurate measure of thyroid function than other methods of free T4 assessment in pregnancy. OH should be treated in pregnancy; IH should not be treated in pregnancy; there is insufficient evidence to treat SCH in TAb negative women in pregnancy, with possible benefit to treat SCH in women during pregnancy who are TPOAb positive. Then optimal treatment for maternal hypothyroidism in pregnancy is oral LT4 and it is recommend against using preparations such as T3 or dessicated thyroid – goal of therapy is to normalize TSH in the gestational age specific normal range. Repeat TSH q 4 weeks through 20-24 weeks then at last once between 26 and 32 weeks.*
9. Thyroid disease in pregnancy. ACOG Practice Bulletin No. 37. American College of Obstetricians and Gynecologists. **Obstet Gynecol.** 2002;100:387-396. Reaffirmed 2010. *TSH and free T4 are the TFT's that should be used for diagnosis and management of thyroid disease in pregnancy. Testing for thyroid disease in pregnancy should be done in the presence of symptoms consistent with thyroid disease or personal history of thyroid disease. At this time, routine screening of asymptomatic pregnant women for hypothyroidism is not recommended. Isolated thyroid nodules should be investigated in pregnancy.*

Revised December 11, 2011.

Notification to Users

These algorithms are designed to assist the primary care provider in the clinical management of a variety of problems that occur during pregnancy. They should not be interpreted as a standard of care, but instead represent guidelines for management. Variation in practices should take into account such factors as characteristics of the individual patient, health resources, and regional experience with diagnostic and therapeutic modalities.

The algorithms remain the intellectual property of the University of North Carolina at Chapel Hill School of Medicine. They cannot be reproduced in whole or in part without the expressed written permission of the school.